SS Innovations International, Inc. Announces Major Regulatory Approvals and Expansion
SS Innovations International, Inc. Announces Major Regulatory Approvals, Global Expansion, and Path to U.S. and EU Markets
Key Highlights for Investors
- Regulatory Approval: SS Innovations has secured regulatory approval for its flagship SSi Mantra surgical robotic system in four new countries: Colombia, Oman, Sri Lanka, and Kenya.
- Global Footprint: The SSi Mantra system is now approved in a total of eleven countries, including India, Ecuador, Philippines, Guatemala, Indonesia, Ukraine, and the United Arab Emirates.
- Installed Base and Usage: As of December 31, 2025, SSi Mantra’s installed base reached 168 units across ten countries, with 7,885 cumulative surgeries performed, including significant numbers in cardiac (390) and pediatric (121) procedures.
- Telesurgery Leadership: Over 150 telesurgeries have been successfully conducted using the SSi Mantra, highlighting its advanced remote surgical capabilities.
- Cost-Effective Technology: The company emphasizes its competitive cost advantage, advanced features, user-friendly design, and ease of training, positioning it well for underpenetrated global markets.
- Upcoming U.S. and EU Milestones: The company expects the U.S. FDA to complete its review of the 510(k) premarket notification for SSi Mantra by mid-2026. A European Union CE marking certification is anticipated within 2026.
- Product Features: The SSi Mantra is a modular, multi-arm robotic system with a 3D 4K monitor, touch panel, real-time imaging, and support for over 40 types of surgical instruments, including specialized tools for pediatric and cardiac surgery. It also offers a portable tele-surgeon console.
- Clinical Validation: The system has been clinically validated in India across more than 100 different surgical procedures.
Important Information for Shareholders
Potential Price Sensitivity: The expansion of regulatory approvals into new markets directly increases the company’s addressable market and revenue potential. Entry into underpenetrated regions (such as Colombia, Oman, Sri Lanka, and Kenya) with a cost-effective solution may accelerate adoption and competitive positioning, potentially impacting share value positively.
The anticipated U.S. FDA clearance (mid-2026) and pursuit of European Union CE marking are critical milestones. Successful achievement of these regulatory goals could significantly expand the company’s presence in two of the world’s largest medical device markets, and may be a catalyst for substantial share price appreciation.
The company’s strong installed base (168 units) and high number of surgeries (7,885) demonstrate growing market acceptance. The telesurgery capability and multi-specialty support further differentiate SS Innovations in the global surgical robotics industry.
Investors should note the company’s forward-looking statements regarding regulatory timelines, market expansion, and product adoption, which are subject to risks and uncertainties.
Detailed Summary
SS Innovations International, Inc. (Nasdaq: SSII), a developer of innovative surgical robotic technologies, announced major regulatory approvals for its SSi Mantra surgical robotic system in Colombia, Oman, Sri Lanka, and Kenya. These approvals were granted by leading regulatory authorities: INVIMA (Colombia, Nov 2025), DGPA&DC (Oman, Nov 2025), NMRA (Sri Lanka, Jan 2026), and PPB (Kenya, Jan 2026).
The SSi Mantra now holds regulatory clearance in eleven countries, including India, Ecuador, Philippines, Guatemala, Indonesia, Ukraine, and the UAE. This robust international footprint positions SS Innovations to address high-growth, underpenetrated markets.
According to Chairman and CEO Dr. Sudhir Srivastava, SS Innovations is committed to democratizing access to cutting-edge robotic surgery, especially in underserved regions. The company is also actively pursuing entry into the U.S. and European markets, anticipating FDA clearance by mid-2026 and CE marking within the same year.
The SSi Mantra surgical robotic system is designed to be user-friendly, modular, and highly advanced. It features 3 to 5 robotic arms, an ergonomic open-faced surgeon command center, a large 3D 4K monitor, real-time imaging, and a suite of over 40 robotic endo-surgical instruments. The optional SSi MantrAsana Tele Surgeon Console enhances portability and enables telesurgery, expanding the system’s versatility.
Clinical validation has been achieved in India, with the SSi Mantra used in more than 100 distinct surgical procedures. As of the end of 2025, the installed base reached 168 units across ten countries, performing almost 8,000 surgeries, including pediatric and cardiac specialties, and more than 150 telesurgeries.
SS Innovations is headquartered in India, with plans to expand its global presence further. The company’s vision is to make robotic surgery affordable and accessible to a larger segment of the global population.
Investor and Media Contacts
Disclaimer
This article contains forward-looking statements based on information provided by SS Innovations International, Inc. These statements are subject to risks and uncertainties, including regulatory timelines, market adoption, competition, and other factors that may affect actual results. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The information presented does not constitute investment advice.
View SS Innovations International, Inc. Historical chart here
